AI in the drug discovery pipeline

The results show the promise of an appropriate AI framework to accelerate the discovery of activity between molecules and targets, particularly in receptors with importance to therapeutic treatments for AD. For example, targeting beta-adrenergic-2 receptors because of its relation to neurogenesis and synaptic disfunction. Moving to later stages of the proposed pipeline will highlight and validate the potential of our molecules in the field of medicine and AD.